CLRB — Cellectar Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1279704 ·
Last close
$0.92
Market Cap
$9.24M
52W High
$4.70
52W Low
$0.90
ADV30
142,323
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -8,104,015 | -7,974,743 | 29,743,263 | 24,582,115 | 7,327,897 |
| Jun 2026 | 0 | — | -7,196,012 | -6,930,653 | 36,639,086 | 33,993,982 | 6,767,253 |
| Mar 2026 | 0 | — | -5,793,942 | -5,653,946 | 11,119,761 | 8,347,090 | 7,784,674 |
| Dec 2025 | 0 | — | -5,690,629 | -5,295,221 | 14,978,321 | 13,196,033 | 6,441,157 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,611,750
Investing CF
$-9,258
Financing CF
$13,031,528
CapEx
$-3,378
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.77
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-289,692,843
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-26,784,598
Pretax Income TTM
$-25,854,563
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,979,844 | -21,791,037 | 14,978,321 | 6,441,157 | 8,537,164 | -23,118,217 |
| Dec 2024 | 0 | -51,777,698 | -44,581,446 | 25,474,047 | 11,179,366 | 14,294,681 | -47,583,001 |
| Dec 2023 | 0 | -38,960,643 | -42,770,610 | 12,075,580 | 27,234,548 | -15,158,968 | -32,376,974 |
| Dec 2022 | 0 | -28,813,773 | -31,792,618 | 21,589,790 | 13,436,546 | 8,153,244 | -25,222,301 |
TTM Snapshot
Revenues TTM
$25,841,416
NetIncome TTM
$-22,323,696
OpCashFlow TTM
—
Assets (Latest)
$36,639,086
Forward EPS
$-2.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GDTC | CytoMed Therapeutics Ltd | $9.27M | $0.78 | — |
| PTN | PALATIN TECHNOLOGIES INC | $9.55M | $5.36 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $9.57M | $2.51 | — |
| BIVI | BIOVIE INC. | $9.61M | $1.00 | — |
| BFRI | Biofrontera Inc. | $8.81M | $0.59 | — |
News headlines (Yahoo Finance, 1h cache)
Cellectar Biosciences, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
Cellectar (CLRB) Q3 2026 Earnings Call Transcript
2026-11-11 03:58 · Yahoo
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-10 12:15 · Yahoo
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Expo
2026-11-04 14:00 · Yahoo
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
2026-11-02 13:00 · Yahoo
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
2026-10-27 11:15 · Yahoo
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Works
2026-10-15 11:00 · Yahoo
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Worksho
2026-09-29 11:30 · Yahoo
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
2026-08-20 14:13 · Yahoo
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
2026-08-17 21:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.